Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.25, Zacks reports.
Kiora Pharmaceuticals Price Performance
Kiora Pharmaceuticals stock opened at $3.25 on Friday. The firm has a 50-day moving average of $3.04 and a 200-day moving average of $3.36. The company has a market cap of $9.89 million, a price-to-earnings ratio of -1.12 and a beta of -0.67. Kiora Pharmaceuticals has a one year low of $2.51 and a one year high of $5.55.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Kiora Pharmaceuticals in a research note on Friday, March 28th.
Kiora Pharmaceuticals Company Profile
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Further Reading
- Five stocks we like better than Kiora Pharmaceuticals
- What is a Secondary Public Offering? What Investors Need to Know
- Constellation Powers Up With Reinforced AI Data Center Strategy
- Where Do I Find 52-Week Highs and Lows?
- Top Analyst-Rated Healthcare Stocks to Watch Now
- Energy and Oil Stocks Explained
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
